Important Update for Sage Therapeutics Investors
The Gross Law Firm is notifying shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE) about an upcoming class action lawsuit. If you purchased shares during the specified class period, it’s crucial to consider taking steps regarding a potential lead plaintiff appointment.
Details of the Class Period
The class period spans from April 12, 2021, to July 23, 2024. This timeframe is important for anyone looking to get involved in the legal proceedings. Note that being appointed as the lead plaintiff isn’t necessary for participating in any recovery.
Overview of Allegations
The main allegations in the complaint claim that, during the class period, the defendants made significantly false and misleading statements concerning certain treatments. Specifically, they stated that the neuroactive steroid Zuranolone for postpartum depression was less effective for treating Major Depressive Disorder (MDD) than they led investors to believe. This raises doubts about the chances of FDA approval for Zuranolone's New Drug Application (NDA) in its current form. Additionally, claims regarding the effectiveness of both SAGE-718 for Mild Cognitive Impairment related to Parkinson’s Disease and SAGE-324 for essential tremor have faced scrutiny, suggesting that the public was misinformed about the clinical and commercial potential of these treatments.
Registration and Important Deadlines
Shareholders must register for the class action by October 28, 2024. If you're interested in participating, it’s essential to act quickly to reserve your spot in this significant legal matter. Once registered, shareholders can take advantage of a portfolio monitoring service, which will keep them updated on the case's developments.
The Gross Law Firm’s Role
The Gross Law Firm is recognized for standing up for investors who have been misled by corporate dishonesty and fraud. Their mission to hold corporations accountable helps protect shareholders’ rights and seeks recovery for those impacted by financial misconduct. Participation in this class action incurs no costs or obligations for investors.
Contact Information
If you have any questions, you can reach out to the Gross Law Firm at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit claims that Sage Therapeutics provided misleading information about the effectiveness of its treatments, which negatively influenced stock prices.
How can I register for the class action?
Shareholders who wish to participate should register their details by the October 28, 2024 deadline.
What are the potential benefits of joining the class action?
Joining the class action could offer a means to recover losses caused by misleading statements from the company.
Is there a cost to participate in the lawsuit?
Participation in the class action is free and comes without any obligation.
Who can I contact for more information?
For any inquiries about the lawsuit or registration, shareholders can get in touch with The Gross Law Firm directly.